MARKET WIREYahoo Finance • 22h ago
Standard BioTools Announces Agreement to Sell Microfluidics Business to ARCHIMEDYahoo Finance report covering Standard BioTools Inc. (LAB) market action, institutional positioning, and fundamental catalysts.
Why LAB Stock Traded Steady Today — RQD Quant Desk Flash
$0.61 -0.02% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $0.61
Standard BioTools Inc. (LAB) carries a Roarable Rating of E (Strong Sell) with 27/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $240.7M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on LAB Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is LAB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Standard BioTools Inc. (NASDAQ: LAB) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 27/100 at a spot price of $0.61 (-0.02% 1D, market cap $240.7M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, LAB ranks #885 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does LAB compare to NAUT and QTRX in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), LAB carries a Roarable E (27/100 RQD), trailing P/E of N/A, gross margin of 49.9%, and ROIC of -28.7%. By comparison, NAUT (Nautilus Biotechnology Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $347.7M) and QTRX (Quanterix Corporation) posts a E grade (22/100 RQD, P/E N/A, ROIC -35.0%, cap $137.4M). Among the 5-stock peer group, LAB leads on earnings multiple (N/A) while CTKB leads on capital efficiency (-12.7% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for LAB?
▼
Per LAB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001162194), Standard BioTools Inc. generated $85.3M in revenue (-6.2% YoY), -$74.9M in net income, and -$82.6M in free cash flow against $567.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $0.61 (-0.19%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (27/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.3% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk E
Each axis scored 0–20
12M PRICE TARGET CONE-14.8% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LAB)Realized 20D OHLCV Swing Band: ±11.3%
Deterministic 5-Pillar Attribution (27/100 Composite)
🔍 WHY LAB SCORES 27/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+8/20 pts (30% of score)
20D Institutional Volume Accumulation (±11.3% realized swing band)
▲ #2 Bullish Driver: Macro Regime Fit+6/20 pts (22% of score)
FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 38.8 (NEUTRAL RANGE)
▼ #1 Drag / Risk Factor: Cash Engine Quality4/20 pts (-16 pt drag)
Capital intensity & 0% operating margin leave 16 pts on the table
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$0.66-3% Next Q
35
Q2 (-2Q)Grade E$0.64-3.1% Next Q
32
Q3 (-1Q)Grade E$0.62-1.6% Next Q
30
CurrentGrade E$0.61-10.3% Hist 90D α
27
Trajectory: E (35) → E (27)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a LAB Turnaround Squeeze
While LAB currently carries a cautious 27/100 (E) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.68) and Max Pain ($0.64) forces dealer call-delta covering toward $1.81.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $LAB• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “LAB Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why LAB Stock Traded Steady Today — RQD Quant Desk Flash
Standard BioTools Inc. (LAB) slipped -0.02% to $0.61, trading at 2% of its 52-week range ($0.59 – $1.72). Stretched risk/reward at current multiples (-29% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 2% of its 52-week range ($0.59 – $1.72) with RSI-14 at 38.8 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±11.3% around $0.61 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 49.9% gross margin and $0 annual free cash flow.
Live LAB Headlines & Catalysts
MARKET WIRETradingView • 1d ago
Standard BioTools Inc. Estimates – NASDAQ:LABTradingView report covering Standard BioTools Inc. (LAB) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
A 1-for-20 to 1-for-40 reverse split is proposed in Standard BioTools (LAB)'s Treeline merger.Stock Titan report covering Standard BioTools Inc. (LAB) market action, institutional positioning, and fundamental catalysts.
MARKET WIREGenomeWeb • 1d ago
Standard BioTools to Sell Microfluidics Business to ArchimedGenomeWeb report covering Standard BioTools Inc. (LAB) market action, institutional positioning, and fundamental catalysts.
MARKET WIREInvesting.com UK • 1d ago
Standard BioTools sells Microfluidics unit to ARCHIMED By Investing.comInvesting.com UK report covering Standard BioTools Inc. (LAB) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESimply Wall St • 1d ago
October 2026's Top Picks: Promising Penny StocksSimply Wall St report covering Standard BioTools Inc. (LAB) market action, institutional positioning, and fundamental catalysts.
MARKET WIREhttps://www.siam.in/ • 1d ago
Standard (LAB) Suffers -1.07% Decline on Heavy Selling 2026-10-20 - Pullback Tradehttps://www.siam.in/ report covering Standard BioTools Inc. (LAB) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo • 4d ago
Will TXG Stock Ever Get Back To Its Old High?For questions about this article or underlying research, email help@trefis.com.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring LAB)
- ✓Walkthrough of LAB's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
LAB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -35.11%🛡️ HOLDING TREND SUPPORT
2026-11-03O $0.62H $0.62L $0.61C $0.61VOL 1.00M
RES: $0.74SUP: $0.59SMA50: $0.68SMA200: $0.91
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
LAB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. -6.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on LAB today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for LAB. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for LAB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LAB)
Health Care Rank #885 of 1015
⚔️ NAUT vs LAB Full Matrix →
1. Head-to-Head Health Care Peer Comparison (LAB vs. NAUT, QTRX, SEER, CTKB)
Industry: Biotechnology: Laboratory Analytical Instruments (21 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, Standard BioTools Inc. (LAB) ranks #885 by composite RQD confidence (27/100, grade E) and #549 by equity capitalization ($240.7M). Within this direct 5-issuer industry benchmark cohort, LAB leads on earnings valuation at N/A trailing P/E, while CTKB leads on capital efficiency and profitability with -12.7% ROIC and 51.8% gross margin. CTKB currently holds the highest overall quantitative score in the immediate peer group at 45/100 (D) compared with LAB at 27/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| LAB
ACTIVE
Standard BioTools Inc. | E | 27/100 | — | 49.9% | -28.7% | -0.02% | $240.7M | Benchmark Subject |
| NAUT Nautilus Biotechnology Inc. | D- | 43/100 | — | — | -35.0% | -14.47% | $347.7M | /naut-vs-lab → |
| QTRX Quanterix Corporation | E | 22/100 | — | 46.8% | -35.0% | -3.27% | $137.4M | /qtrx-vs-lab → |
| SEER Seer Inc. (Class A) | E | 26/100 | — | 51.1% | -29.1% | +2.98% | $93.0M | /seer-vs-lab → |
| CTKB Cytek Biosciences Inc. | D | 45/100 | — | 51.8% | -12.7% | -5.87% | $796.8M | /ctkb-vs-lab → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001162194 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), Standard BioTools Inc. (LAB) reported GAAP revenue of $85.3M (-6.2% vs. FY2024 revenue of $91.0M , and -19.8% cumulative change since FY2023) , GAAP net income of -$74.9M, operating cash flow of -$74.3M, and free cash flow of -$82.6M (+45.6% YoY). On the balance sheet, LAB closed FY2025 with $567.8M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $85.3M | -$74.9M | -$74.3M | -$82.6M | $567.8M | — |
| FY2024 (FY) | 2024-12-31 | $91.0M | -$138.9M | -$143.5M | -$151.8M | $612.3M | — |
| FY2023 (FY) | 2023-12-31 | $106.3M | -$74.7M | -$43.3M | -$43.3M | — | — |
3. LAB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs LAB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Standard BioTools Inc. (NASDAQ: LAB) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 27/100 at a spot price of $0.61 (-0.02% 1D, market cap $240.7M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, LAB ranks #885 in composite RQD confidence.
How does LAB compare to NAUT and QTRX in the Health Care sector?
Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), LAB carries a Roarable E (27/100 RQD), trailing P/E of N/A, gross margin of 49.9%, and ROIC of -28.7%. By comparison, NAUT (Nautilus Biotechnology Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $347.7M) and QTRX (Quanterix Corporation) posts a E grade (22/100 RQD, P/E N/A, ROIC -35.0%, cap $137.4M). Among the 5-stock peer group, LAB leads on earnings multiple (N/A) while CTKB leads on capital efficiency (-12.7% ROIC).
What are the biggest fundamental strengths and SEC risk factors for LAB?
Per LAB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001162194), Standard BioTools Inc. generated $85.3M in revenue (-6.2% YoY), -$74.9M in net income, and -$82.6M in free cash flow against $567.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Where is LAB trading relative to its 50-day, 200-day, and 52-week technical levels?
LAB last traded at $0.61 (-0.02% on volume of 1,708,230 shares), positioning the stock -10.29% below its 50-day simple moving average ($0.68) and -32.97% below its 200-day simple moving average ($0.91). Across its 52-week range of $0.59 to $1.72, LAB sits at the 1.8% percentile with a 14-day RSI of 38.8 (NEUTRAL RANGE) and an implied next-earnings move of ±11.3% ($1.00 to $0.68).
ROARABLE RATING BRIEF • RQD 27/100 (E)
✓ SEC XBRL & RQD VERIFIED
LAB — Standard BioTools Inc.: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
Standard BioTools Inc. (LAB) earns a live Roarable RQD composite score of 27/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $0.61 (-0.02% 1D, market capitalization $240.7M).
- Fundamental Cash Engine (3/20): Anchored by return on invested capital (ROIC) of -28.7%, gross margin of 49.9%, operating margin of -60.0%, and free cash flow yield of —.
- Whale 13F & Options Flow (8/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (6/20) + Forensic Balance Sheet (5/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 4/9, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
Standard BioTools Inc. (LAB) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Laboratory Analytical Instruments industry. Per the recent news wire, the company has announced an agreement to sell its Microfluidics business to ARCHIMED. Revenue for FY 2025 was $85.3M .
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Standard BioTools Inc. (LAB) reported $85.3M in annual revenue (up from $91.0M in FY2024, -6.2% YoY) and -$74.9M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($106.3M revenue, -$74.7M net income) through FY2025, LAB scaled operating cash flow to -$74.3M and free cash flow to -$82.6M, backed by $567.8M in total assets against $0 in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (E • RQD 27/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 8/20. With Fundamental Cash Engine at 3/20 and Institutional Whale Flow at 8/20, sustained execution supports upside toward the upper end of the $0.59 – $1.72 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
The sector classification of Health Care and industry of Laboratory Analytical Instruments is the only sector context provided.
- Key Question #1: Can LAB sustain or expand its -60.0% operating margin and -28.7% ROIC against Biotechnology: Laboratory Analytical Instruments peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $85.3M and free cash flow of -$82.6M, how will capital allocation balance growth reinvestment against $0 in total debt?
- Key Question #3: How sensitive is LAB's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
LAB Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Standard BioTools Inc. (LAB) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance • 22h ago
Standard BioTools Announces Agreement to Sell Microfluidics Business to ARCHIMED Yahoo Finance report covering Standard BioTools Inc. (LAB) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 1d ago
Standard BioTools Inc. Estimates – NASDAQ:LAB TradingView report covering Standard BioTools Inc. (LAB) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
A 1-for-20 to 1-for-40 reverse split is proposed in Standard BioTools (LAB)'s Treeline merger. Stock Titan report covering Standard BioTools Inc. (LAB) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE GenomeWeb • 1d ago
Standard BioTools to Sell Microfluidics Business to Archimed GenomeWeb report covering Standard BioTools Inc. (LAB) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Investing.com UK • 1d ago
Standard BioTools sells Microfluidics unit to ARCHIMED By Investing.com Investing.com UK report covering Standard BioTools Inc. (LAB) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Simply Wall St • 1d ago
October 2026's Top Picks: Promising Penny Stocks Simply Wall St report covering Standard BioTools Inc. (LAB) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE https://www.siam.in/ • 1d ago
Standard (LAB) Suffers -1.07% Decline on Heavy Selling 2026-10-20 - Pullback Trade https://www.siam.in/ report covering Standard BioTools Inc. (LAB) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo • 4d ago
Will TXG Stock Ever Get Back To Its Old High? For questions about this article or underlying research, email help@trefis.com.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
LAB Bull vs. Bear Conversation Board — What's Your Call at $0.61?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON LAB 🐻 33% BEARISH CONVICTION
QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH
🎯 Target: $0.71 (+16.4%)
📌 Pinned Debate Pending sale of the Microfluidics business and a proposed Treeline merger could reshape the company's asset base and capital structure.
Picked up a starter position in LAB in my $100K Virtual Cash book at $0.61. Pending sale of the Microfluidics business and a proposed Treeline merger could reshape the company's asset base and capital structure.. Trading inside a $0.59–$1.72 52-week range with 0.0% FCF yield gives solid downside support if Biotechnology: Laboratory Analytical Instruments multiples expand this quarter.
VolSurface_Trader 🐂 BULL
Both sides have a point here — LAB's 5/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.
RE RedlineAuditor RQD DEBATE OPENER • Accounting Quality Watch 🐻 BEARISH
🎯 Target: $0.50 (-18.0%)
Spot @ $0.61 ROIC of -28.7%, 0% FCF yield, and an Altman Z of 0.2 indicate the business is not currently generating returns or cash to support its b
Fading this rally in LAB at $0.61. ROIC of -28.7%, 0% FCF yield, and an Altman Z of 0.2 indicate the business is not currently generating returns or cash to support its balance sheet.. With a beta of 1.0 and the stock sitting at $0.61 (52-wk range $0.59–$1.72), the easy multiple expansion is already priced in.